|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ѫ����Ƥ�������� |
|
Ƥ������ |
| ��������������� | |
|
���M |
|
Ϳ��ͥ |
| PubMed | |
|
Article by |
|
Article by |
Ѫ����Ƥ�������Ӻ�Ƥ������
���M, Ϳ��ͥ
���пƼ���ѧͬ��ҽѧԺ����Э��ҽԺ, �人430022
Ѫ����Ƥ����������һ�߶������Ѫ����Ƥϸ����˿����ԭ,����Ҫ�Ĵ�Ѫ����������֮һ,���������ԺͲ�����Ѫ�����ɡ�Ѫ����Ƥ�����������������Եطֲ���Ѫ����Ƥϸ������,�����Ұ��ἤø���ԡ�Ѫ����Ƥ�������Ӽ���������Ƥ�������б��,����Ƥ�������ķ�������չ��ת���Լ��ж�Ƥ���������������й�,����Ѫ����Ƥ��������ΪƤ�����������ƿ����µ�;����
[2] Ruckman J, Green LS, Beeson J, et al. 2'-Fluoropyrimidine RNAbased aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGFinduced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem, 1998, 273 (32):20556-20567.
[3] Shen BQ, Lee DY, Gerber HP, et al. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem, 1998, 273(45):29979-29985.
[4] Szabo S, Sandor Z. The diagnostic and prognostic value of tumor angiogenesis. Eur J Surg Suppl, 1998, (582):99-103.
[5] Marti HH, Risan W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A, 1998, 95(26):15809-15814.
[6] Akiri G,Nahari D, Finkelstein Y, et al. Regulation of vascular endo thelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Onco gene, 1998, 17(2):227-236.
[7] Raleigh JA, Catkins-Adams DP, Rinker LH, et al. Hypoxia and vas cular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res, 1998, 58(17):3765-3768.
[8] Rak J, Yu JL, Klement G, et al. Oncogenes and angiogenesis:signa ling three-dimensional tumor growth. J Investig Dermatol Symp Proc, 2000, 5(1):24-33.
[9] Tsao MS, Liu N, Nicklee T, et al. Angiogenesis correlates with vas cular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res, 1997, 3(10):1807-1814.
[10] Giatromanolaki A, Koukourakis MI, Kakolyris S, et al. Vascular en dothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res, 1998, 4 (12):3017-3024.
[11] Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun. 1998, 251 (1):287-290.
[12] Salven P. Heikkila P, Joonsuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer, 1997, 76(7):930-934.
[13] Lacal PM, Failla CM, Pagani E,et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol, 2000, 115 (6):1000-1007.
[14] Birck A, Kirkin AF, Zeuthen J, et al. Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res, 1999, 9 (4):375-381.
[15] Bayer-Garner IB. Hough AJ Jr, Smoller BR. Vascular endothelialgrowth factor expression m malignant melanoma:prognostic versus diagnostic usefulness. Mod Pathol, 1999, 12 (8):770-774.
[16] Bielenberg DR, Bucana CD, Sanchez RR, et al. Progressive growth ofinfantile cutaneous hemangiomas is directly correlated with byperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor. IFN-beta. Int J Oncol, 1999, 14(3):401-408.
[17] Maiolino P, De Vico G, Restucci B. Expression of vascular endotheli al growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. J Comp Pathol, 2000, 123 (2-3):141-145.
[18] Melnyk O, Zimmerman M, Kim KJ, et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol, 1999, 161 (3):960-963.
[19] Wang G, Dong Z, Xu G,et al. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol, 1998, 124 (11):615-620.
[20] Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev, 1998, 17(2):155-161.
[21] Zhu Z, Rockwell P, Lu D, et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage displaylibrary. Cancer Res, 1998, 58(15):3209-3214.
[22] Raleigh JA, Catkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res, 1998.58 (17):3765-3768.
[23] Arora N, Masood R, Zheng T, et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res, 1999, 59(1):183-188.
[24] Redondo P, Bandres E, Solano T, et al. Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. Cytokine, 2000, 12(4):374-378.